<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962246</url>
  </required_header>
  <id_info>
    <org_study_id>Alien-Craft</org_study_id>
    <nct_id>NCT01962246</nct_id>
  </id_info>
  <brief_title>Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction</brief_title>
  <acronym>A-C</acronym>
  <official_title>Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stage I：preoperative therapy

        -  Capecitabine plus oxaliplatin with concurrent radiotherapy is superior to surgery alone
           ; Stage II: Perioperative therapy

        -  Perioperative Capecitabine plus oxaliplatin with Concurrent radiotherapy is superior to
           adjuvant Capecitabine plus oxaliplatin alone;

        -  A regimen of Capecitabine plus oxaliplatin(XELOX) improves survival among patients with
           incurable locally advanced or metastatic adenocarcinoma of stomach and gastroesophageal
           cancer . The investigators assessed whether the addition of a perioperative regimen of
           XELOX regimen with concurrent radiotherapy to adjuvant alone improves R0 resection rate
           and survival among patients with curable locally advanced adenocarcinoma of stomach and
           gastroesophageal cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Down-staging Rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 year</time_frame>
    <description>Side effects during observation] Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death related to operation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>postoperative chemotherapy,XELOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative Concurrent Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin; Capecitabine</intervention_name>
    <description>Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation</description>
    <arm_group_label>postoperative chemotherapy,XELOX</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxaliplatin; Capecitabine; concurrent radiotherapy</intervention_name>
    <description>Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT</description>
    <arm_group_label>Preoperative Concurrent Chemoradiotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>XRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Disease must be clinically limited to the esophagogastric junction, defined TypeⅡ
             TypeⅢ(From the endoscopic point of view according to the AEG criteria)

          2. Histologically confirmed primary adenocarcinoma

          3. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3M0，

          4. ECOG performance status ≦2

        AEG is defined and described as tumors which have their center within 5cm proximal or
        distal of the anatomical cardia.

        The classification of AEG type I, type II and type III AEG type I: adenocarcinoma of the
        distal esophagus,which usually arises from an area with specialized intestinal metaplasia
        of the esophagus, i Barrett's esophagus, and may infiltrate the esophago-gastric junction
        from above;

          -  AEG type II: true carcinoma of the cardia, arising from the cardia epithelium or short
             segments with intestinal metaplasia at the esophago-gastric junction;

          -  AEG type III: subcardial gastric carcinoma, which infiltrates the esophago-gastric
             junction and distal esophagus from below.

        Exclusion Criteria:

          1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy,
             endoscopic ultrasound and CT scanning.

          2. Patients with primary carcinomas of the esophagus.

          3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past
             5 years, or prior esophageal or gastric surgery.

          4. Patients with evidence of metastatic disease are not eligible.

          5. Patients with a history of seizure disorder who are receiving phenytoin,
             phenobarbital, or other antiepileptic medication.

          6. Patients who cannot fully comprehend the therapeutic implications of the protocol or
             comply with its requirements.

          7. Patients with any medical or psychiatric condition or disease which, in the
             investigator's judgment, would make the patient inappropriate for entry into this
             study.

          8. History of hypersensitivity to fluoropyrimidines, capecitabine, oxaliplatin or the
             ingredients of this product -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qun Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of General Surgery</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Zhao, Doctor</last_name>
      <phone>+8613930162111</phone>
      <email>zhaoqun516@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Qun Zhao, Dortor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>August 27, 2016</last_update_submitted>
  <last_update_submitted_qc>August 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Preoperative Concurrent Chemoradiotherapy</keyword>
  <keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

